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THE PROSTAGLANDINS 
JOHN E. PIKE, PH.D. 
Experimental Chemistry Research , The Upjohn Company. Kalamazoo , Michigan. U. S. A . 
The prostaglandins (PGs) a re a family of natu-
rally occurring, humoral agents characterized by a 
unique. oxygenated. low-molecular-weight. fatty 
acid structure incorporating a 5-membered ring 
(for general references see 11-9)). Examples of the 
structures of some of the more important prosta-
glandins a re shown in Figure l. Since their original 
discovery in the 1930s and the much later elucida-
tion of the structure of the purified prostaglandins 
by Bergstrom and his collaborators at the Karolin-
ska Institute, several developments have been of 
special significance. First and most striking is the 
large number of structural variations within the 
prostanoid family. which has now expanded from 
the first known PGE and PGF stuctures to include 
the PGAs. PGBs. PGCs and PGDs, and to this 
structural diversity one must add the unique bio-
logi c properties assoc iated with each type of mo-
lecular modification. Biologic testing of the prosta-
glandins has uncovered a wide variety of pharma· 
cologic activit ies in a large number of areas and 
this has led to some possible clinical uses for the 
natural compounds and their analogs (Tab . l) 
The pro taglandins are formed by nearly all cells 
from membrane-located stores of polyunsat.urated 
acids bound as phospholipids, and the biologic 
effects of these agents are characteristically seen at 
extremely low concentrations (10 - · gm/ mll. mak-
ing them among the most potent, naturally occur-
ring substances. Another important theme of the 
ongoing research in this area has been t he elucida-
tion of the details of the biosynthesis and metabo-
lism of these agents. In addition to the structural 
characterization of the metabolites, i t seems now 
well established that the prostaglandins a re locally 
active in tis ues and are inactivated rapidly by 
prostaglandin-specific enzymes located close to 
their sites of formation. One can, therefore. think 
of prostaglandins as "local" hormones or auta-
coids. 
Research to date has been less successful in 
answering two more fundamental questions: What 
is the role for prostaglandins in normal body 
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Abbreviations: 
HETE: 12.L-hydroxy-5 .. IO,14-eicosatetraenoic 
acid 
HHT: 12-hydroxy-8. lO·heptadecadienoic acid 
HPETE: hydroperoxide of 12-L-hydroxy-5.8.10, 14· . 
eicosatetraenoic acid. 
PC: prostaglandrn 
RCS: rabbit aona·constricting substance 
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funct ion or in disease states? Why a re the prosta 
gland ins so widely distributed with such appar 
ently diverse effects? Suggestions for possibl£' 
physiologic roles or involvement in pathologic 
states (Tabs. II , III ) do little to answer or c1arif) 
these questions. 
One approach to thinking about prostaglandin, 
has been to see their role as part of an overall 
system (Fig. 2) which encompasses their formation 
from phospholipids and subsequent metabolism 
and inactivation [10 J. Each enzymatic step in this 
sequence is a control point which can be either 
stimu lated or inhibited. and to date we know little 
of the natural mechanisms tha t regulate these 
processes. One thought-provoking idea proposed 
by Vane (11) is that the mechanism of action of 
nonste roida l anti-inflammatory agents (such as 
aspirin and indomethacin) is the inhibition of the 
biosynthesis of prostaglandins. Of course. this is 
only one potential control point and one would 
anticipate that other pharmacologic agents could 
owe thei r actions. at lea t in part. to effects on 
some of these enzymatic steps . The various inter· 
mediates in the pathways would be expected to 
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FIG. 1. Prostaglandin E, and F ,,, struC! ures. 
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TABLE 1. Potential prostaglandin applications 
Labor induction 
Asthma 
Hypertension 
Clot inhibition 
Nasal decongestant 
Abortion 
Menstrual regulation 
Male infert ilit.y 
Blood platelet preservat ion 
Duodenal ulcers 
TABLE II. Possible physiologic roles for prostaglandin s 
Feedback inhibition of neurotransmission 
Luteolysis 
Labor induction 
Closure of ductus arteriosus 
Renal autoregulation 
Sperm t ransport 
Ova transport 
TABLE Ill. Possible int'oll"ement of prostaglandins in 
pathologic states 
Inflammation 
Cholera 
Psoriasis 
Carcinuid tumors 
Burns 
Hypertension 
Aborti on 
Uve itis 
Dysmenorrhea 
IMEMBRANE I 
Contact allergic eczema 
Male sub· fertility 
Asthma 
Toxem ia of pregnancy 
Sickling phenomenon 
(Hypercalcemia of sar comas I 
Periodontal disease 
Fever 
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have unique biologic functions as do the prosta-
gland in themselves. 
Recent studies, especially by Samuelsson , Ham-
berg and their collaborators [12- 16] in Stockholm, 
bave concentrated on the biosynthetic pathway 
which leads from the polyunsatura ted fatty acids 
to what we might call the cia sical prostaglandins. 
and this has led to t he isolation and identification 
of new inte rmediates in this pathway and to some 
important revisions of OUT understanding of the 
elements of t he p rostaglandin system. 
Early mechanistic studies using homogenates of 
sheep seminal vesicular glands indica ted that the 
two oxygen atoms of the 5·membered ring ofPGE. 
were derived from the same oxygen molecule, 
lending support to t he idea that an endoperoxide 
intermediate was formed prior to tbe elabora t ion of 
the characteristic prostaglandin structure . This 
was also supported by the isolation of 12-
hydroxy-8,lO-heptadecadienoic acid (HHT ) and 
malonaldehyde which could be rationalized chemi-
cally as degradation products of the endoperoxide 
(Fig. 3) . Later, two endoperoxides were isola ted 
from short-term incubations of arachidonic acid in 
the presence of p-mercuribenzoate, a nd these were 
named PGG , and P GH , . In aqueous buffer (pH 7.'1 ) 
at 37°C the balf-life of these unstable intermedi-
ates was about 5 min . They were found to have 
ve ry significant a nd potent biologic properties. 
causing rapid and irreversible aggregat ion of 
wa hed human platelets. and the contraction of 
respiratory and vascular mooth muscle. In certain 
in vitro assays they were reponed to have as much 
at 200 times the activi ty of the corresponding PGE , 
or PGF 2". For example. these two intermediates 
a re more potenT and faster in onse t than PGE , in 
contract ing the iso lated umbilica l artery [17 ]. 
In addit ion to compounds deri"ed from endoper-
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FIG. 2. T he prostaglandin system. 
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endoperoxides. anot.her lipooxygenase type path-
way was discovered using platelets. This pathway 
led from arachidonic acid to 12-L-hydroxy-5.8.10. 
14-eicosalerraenoic acid (HETE) "ia the cor re-
sponding hydroperoxide (HPETE I. Interestingly. 
this pathway leading from arachidonic acid to 
HETE is not inhibited b,' aspirin or indomethacin. 
but is blocked by the acetylenic counterpa rt of 
arachidonic acid. 5.8.11-14-eicosatetraynoic acid. 
In addition to HHT and HETE. the suspen-
sions of washed human platelets produced a hemi-
acetal deri,'at i,'e of 8-( I-hydroxy-3-oxopropyD-
9.12- L-dibydroxy-5.1 O-heptadecadienoic acid. ear-
lier called PHD, but later named thromboxane B, 
(Fig. 4) . Hamburg and co-workers [16.18J showed 
that when washed human platelets were treated 
with thrombin. these 3 metabolites were produced 
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FIG. 3. Metabolism of the prostaglandin - endoperox-
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in much larger amounts than the corresponding 
classical prostaglandins, and clearly this enzy-
matic pathway which converts the endoperoxides 
to these newer metabolites is of major importance 
in platelets. In an investigation of the transforma-
t ion of PGG, into the hemiacetal thromboxane B, . 
evidence was also found for a short-lived interme-
diate (half-life of only about 30 sec) which could 
be trapped in the presence of nucleophilic rea-
gents. A structure (Fig. 5) was proposed (or this new 
intermediate which was called thromboxane A, . 
It is believed that a major part of the activity of the 
rabbit aorta-constricting substance (ReS). first 
described by Piper and Vane. is due to thrombox-
ane A,. Measurements of these new metabolites 
have also been made on the perfusates of guinea. 
pig lung. Injection of a rachidonic acid (30 /Lg) 
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FIG. 4. Arachidonic acid metabolism- thromboxane pathway. 
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causes the release of thromboxane B, (654- 2304 
ng). HHT (192- 387 ng). HETE (66-111 ng), PGE, 
(15- 93 gm), and PGF'a (93-171 ng) [19]. While the 
levels of PGE, and PGF,. may be low because of 
substantial metabolism to the corresponding 15-
keto compounds. it is , nevertheless, clear, that the 
new pathway represents a major metabolic route 
and the amounts of thromboxane B, formed are 
especially striking. These studies suggest strongly 
that the thromboxanes have a role in the respira-
tory system and in anaphylactic reactions. 
It will be important to determine whether these 
newer intermediates. t he endoperoxides and their 
metabolites, have special significance in other 
cells. Also. it will be inte resting to see how impor-
tant is the biosynthetic pathway to another series 
of cyclic ethers described earlier by Pace-Asciak 
and Wolfe [20]. In the stomach where these agents 
were first discovered, this biosynthetic conversion 
of arachidonic acid may be a major route. Alread~' 
a report has appeared which documents high levels 
of HETE in psoriatic tissue relative to uninvolved 
skin. These structure!' pose an unusual challenge 
for chemical synthesis, especially for those com-
pounds which are relatively unstable. To date. no 
reports have vel appeared of the synthesis of 
PGG , and PGH,. One chem ical approach to this 
area by Bundy at Upjohn has been the synthesis of 
structural analogs of PG H, in which each of the 
oxygen atoms attached to C-9 or C-ll in the 
endoperoxide structure has been replaced by a 
methylene (C H,) group [21]. These compounds are 
very sta ble chemically and can be used as model 
of t.he natural agents. Like PGH" both ethers are 
powerful constrictors of smooth muscle in vitro and 
also cause platelet aggregation. Especia lly remark-
able is tbeir activity on bronchopulmonary dynam-
ics in the spont.aneously ventilated. pentobarbi tal-
anesthetized dog where they exhibit dramatic 
constrictor properties. 
The recent studies on the biosymhetic aspects of 
the prostaglandin systems have led to a sign ificant 
rethinking of orne of the earlier ideas. First. one 
must consider the likelihood t hat biologic activi-
t ies. resulting from the initia ti on of the pathway 
from arachidonic acid. are due not only to the 
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prostaglandins, but rather to these newer " pre-pri-
mary" prostaglandins and their metabolites, which 
may in certain systems represent a major pathway. 
Also. pharmacologi c agents such as aspirin may 
owe their activitv not to an inhibition of the 
biosynthesis of prostaglandins themselves, but 
rather to their ability to prevent the production of 
the newer endoperoxides or t hromboxanes. 
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